Crossing the blood-brain barrier with AAV vectors

Area of Science:

• Neuroscience
• Gene Therapy
• Biotechnology

Background:

• Central nervous system (CNS) diseases pose treatment challenges due to the blood-brain barrier (BBB) restricting drug entry.
• Adeno-associated virus (AAV) vectors offer potential for CNS gene therapy, but efficiency is often limited.
• AAV9 is known to cross the BBB and transduce astrocytes, yet its efficacy requires improvement.

Purpose of the Study:

• To review recent advancements in AAV vector crossing of the BBB for CNS disease treatment.
• To summarize AAV serotypes applicable to CNS disorders.
• To discuss mechanisms and methods for enhancing AAV transduction efficiency across the BBB.

Main Methods:

• Review of current literature on AAV vectors and BBB crossing.
• Analysis of AAV serotypes and their CNS application potential.
• Examination of directed evolution techniques for AAV variant development.

Main Results:

• AAV directed evolution technology has yielded variants with significantly enhanced BBB crossing efficiency compared to wild-type AAV9.
• Several AAV serotypes demonstrate potential for CNS disease gene therapy.
• Mechanisms of AAV BBB crossing and transduction are under active investigation.

Conclusions:

• AAV vectors, particularly those developed through directed evolution, represent a promising strategy for overcoming BBB limitations in CNS gene therapy.
• Further research into AAV BBB crossing mechanisms is crucial for optimizing therapeutic delivery.
• Enhanced AAV variants hold potential for more effective treatment of CNS diseases.